Andere Kunden interessierten sich auch für
![Penile and Urethral Cancer, an Issue of Urologic Clinics]( "Penile and Urethral Cancer, an Issue of Urologic Clinics")
Penile and Urethral Cancer, an Issue of Urologic Clinics110,99 €![Small Renal Mass, an Issue of Urologic Clinics]( "Small Renal Mass, an Issue of Urologic Clinics")
Small Renal Mass, an Issue of Urologic Clinics87,99 €![Diagnosis, Evaluation, and Treatment of Non-Muscle Invasive Bladder Cancer: An Update, an Issue of Urologic Clinics]( "Diagnosis, Evaluation, and Treatment of Non-Muscle Invasive Bladder Cancer: An Update, an Issue of Urologic Clinics")
Diagnosis, Evaluation, and Treatment of Non-Muscle Invasive Bladder Cancer: An Update, an Issue of Urologic Clinics81,99 €![Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics]( "Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics")
Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics81,99 €![Treating the Adult Neurogenic Bladder, an Issue of Urologic Clinics]( "Treating the Adult Neurogenic Bladder, an Issue of Urologic Clinics")
Treating the Adult Neurogenic Bladder, an Issue of Urologic Clinics110,99 €![Robotic Urology: The Next Frontier, an Issue of Urologic Clinics]( "Robotic Urology: The Next Frontier, an Issue of Urologic Clinics")
Robotic Urology: The Next Frontier, an Issue of Urologic Clinics87,99 €![Prostate Cancer Genetics: Changing the Paradigm of Care, an Issue of Urologic Clinics]( "Prostate Cancer Genetics: Changing the Paradigm of Care, an Issue of Urologic Clinics")
Prostate Cancer Genetics: Changing the Paradigm of Care, an Issue of Urologic Clinics89,99 €
PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.